Biotech & Medicine
185 articles RSS
WHO Declares Bundibugyo Ebola Outbreak in DRC and Uganda a Public Health Emergency of International Concern
A rare Bundibugyo virus outbreak with no licensed vaccines or treatments has been declared a PHEIC, with over 650 suspected cases and 160 suspected deaths across three DRC provinces and Uganda.
Siemens Healthineers Wins FDA 510(k) Clearance for Six AI-Powered Artis Interventional Imaging Systems With Optiq Deep-Learning Chain
Six Artis interventional imaging platforms with the Optiq AI deep-learning imaging chain cleared by FDA on May 12, six months after RSNA 2025 debut.
Max Planck Team Maps Cell-Surface Sugar Code at Nanometre Resolution, Revealing Cancer and Immune Signatures
Scientists have developed Glycan Atlasing, a super-resolution technique that reads shifting sugar patterns on cell surfaces to distinguish cancer stages from healthy tissue and activated from resting immune cells.
FDA Approves First ctDNA-Guided Adjuvant Immunotherapy for Bladder Cancer, Rewriting the Post-Surgery Treatment Playbook
Atezolizumab becomes the first therapy cleared for use only in patients whose blood tests reveal molecular residual disease after bladder removal surgery.
FDA Approves Baxfendy, the First Aldosterone Synthase Inhibitor for Uncontrolled Hypertension
AstraZeneca's baxdrostat (Baxfendy) became the first aldosterone synthase inhibitor approved in the US on May 18, 2026, giving the estimated 23 million Americans whose blood pressure remains uncontrolled on two or more drugs a new mechanistic option.
Sleep Brain Waves Predict Dementia Risk Decades Before Symptoms, Large Study Finds
A machine-learning analysis of sleep EEG data from 7,105 adults found that each 10-year gap between brain age and chronological age raises dementia risk by 39%.
Fractyl Health Wins European Clearance for First GLP-1 Gene Therapy Clinical Trial, Aiming to Replace Daily Injections With a One-Time Pancreas Edit
Fractyl Health received authorization in the Netherlands to run the world's first clinical trial of an AAV-based GLP-1 gene therapy for type 2 diabetes, targeting patients who cannot sustain daily injections.
Cytisinicline Heads Toward FDA Decision as Long-Term Safety Data Backs First New Smoking Cessation Drug in Two Decades
Fresh 52-week safety data presented at ATS 2026 reinforce cytisinicline's profile ahead of a June 20 FDA decision that could bring the first new smoking cessation drug to US patients since 2006.
Nine Weeks of Immunotherapy Before Surgery Leaves Every Bowel Cancer Patient Relapse-Free After 33 Months in NEOPRISM-CRC Trial
A UK trial of preoperative pembrolizumab for MMR-deficient colorectal cancer shows zero relapses across all 32 patients after nearly three years of follow-up.
Encoded's ETX101 Cuts Dravet Seizures 76% at Dose Level 3 and Tracks Toward Neurotypical Development in Children Treated Before Age 2
An AAV9 gene-regulation therapy delivered durable, dose-dependent seizure control and early signs of neurodevelopmental rescue through 52 weeks, just as the pivotal study begins dosing.
FDA Grants Sonrotoclax Accelerated Approval as First BCL-2 Inhibitor for Relapsed/Refractory Mantle Cell Lymphoma
BeOne Medicines' Beqalzi clears the FDA on a 52% overall response rate in 103 post-BTK patients, becoming the first BCL-2 inhibitor specifically approved for MCL and setting up a head-to-head with AbbVie and Roche's off-label Venclexta.
FDA Approves Enhertu for Two HER2-Positive Early Breast Cancer Indications, Moving the AstraZeneca-Daiichi ADC Into Curative-Intent Treatment
AstraZeneca and Daiichi Sankyo's trastuzumab deruxtecan won simultaneous neoadjuvant and adjuvant approvals on May 15, backed by 927-patient DESTINY-Breast11 and 1,635-patient DESTINY-Breast05 Phase III trials.